# Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM

> **NCT05199090** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 126 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** MBL949
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05199090
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-02-10
- **Primary completion:** 2023-05-11
- **Final completion:** 2023-05-11
- **Target enrollment:** 126 (ACTUAL)
- **Why stopped:** The tolerability to benefit ratio based on maximum weight loss observed was not considered favorable at the doses studied and the study was terminated early
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05199090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05199090, "Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05199090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*